Alitair Pharmaceuticals Inc., of Morristown, N.J., said the FDA granted orphan drug designation to its bronchiectasis candidate, Erdosteine, which is approved for chronic obstructive pulmonary disease and chronic bronchitis in 50 countries outside the U.S.